TG Therapeutics, Inc. $TGTX Stock Holdings Decreased by WINTON GROUP Ltd

WINTON GROUP Ltd decreased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 57.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 15,677 shares of the biopharmaceutical company’s stock after selling 21,146 shares during the quarter. WINTON GROUP Ltd’s holdings in TG Therapeutics were worth $861,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of TGTX. EverSource Wealth Advisors LLC grew its stake in TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 365 shares in the last quarter. Hantz Financial Services Inc. raised its stake in TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 560 shares in the last quarter. Covestor Ltd lifted its holdings in TG Therapeutics by 563.0% during the 4th quarter. Covestor Ltd now owns 1,810 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 1,537 shares during the last quarter. Pingora Partners LLC lifted its holdings in TG Therapeutics by 31.2% during the 4th quarter. Pingora Partners LLC now owns 2,100 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 500 shares during the last quarter. Finally, Harbor Investment Advisory LLC acquired a new position in shares of TG Therapeutics in the 2nd quarter worth approximately $96,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Up 0.2%

NASDAQ:TGTX opened at $54.00 on Tuesday. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The stock has a 50 day moving average of $53.61 and a 200-day moving average of $43.94. The firm has a market capitalization of $8.27 billion, a PE ratio of 19.71, a price-to-earnings-growth ratio of 2.31 and a beta of 1.67. TG Therapeutics, Inc. has a 52 week low of $26.76 and a 52 week high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The company had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. During the same period last year, the business posted $0.17 EPS. The company’s revenue for the quarter was up 70.2% on a year-over-year basis. Analysts predict that TG Therapeutics, Inc. will post 0.92 EPS for the current year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total value of $274,800.00. Following the sale, the director directly owned 168,640 shares of the company’s stock, valued at $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.87% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TGTX. Jefferies Financial Group reiterated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. Bank of America lifted their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Zacks Research lowered shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, September 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $63.00.

TG Therapeutics Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company’s research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics’ principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.